Aimée Dallob
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Antiplatelet Therapy and Cardiovascular Diseases, Eicosanoids and Hypertension Pharmacology, Dementia and Cognitive Impairment Research, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers(2000)355 cited
- → A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors(1996)281 cited
- → The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia(1999)182 cited
- → Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort(2015)98 cited
- → Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor(2003)92 cited
- → The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness(1994)89 cited
- Enhanced serotonin receptor activity after chronic treatment with imipramine or amitriptyline.(1979)
- → High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid(2015)72 cited
- → Effects of chronic antidepressant treatment on serotonin receptor activity in mice(1983)52 cited
- → Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects(2008)46 cited